Long-term aspirin use and mortality in women

Archives of Internal Medicine

Volumn 167, Issue 6, 2007, Pages 562-572

  Chan, Andrew T ^a,b   Manson, JoAnn E ^b,c   Feskanich, Diane ^b   Stampfer, Meir J ^b,c   Colditz, Graham A ^b,c   Fuchs, Charles S ^b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTHRITIS; ARTICLE; CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG USE; FEMALE; HEADACHE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; STROKE;

ADULT; AGE FACTORS; ASPIRIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK; RISK FACTORS; UNITED STATES;

EID: 34047137888     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.6.562     Document Type: Article

References (49)

1. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep. 2005;53:1-89.
2. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
3. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233-241.
4. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
5. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer [published correction appears in N Engl J Med. 2003;348:1939]. N Engl J Med. 2003;348:883-890.
6. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328-336.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71-86.
8. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
9. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study; a randomized controlled trial. JAMA. 2005;294:47-55.
10. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521-527.
11. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51-65.
12. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119:837-839.
13. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140:1016-1019.
14. Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke. 1999;30:1764-1771.
15. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
16. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609-614.
17. Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk of colorectal adenoma. Ann Intern Med. 2004;140:157-166.
18. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914-923.
19. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164:1519-1524.
20. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96:1856-1865.
21. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004;351:2694-2703.
22. Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body weight and longevity: a reassessment. JAMA. 1987;257:353-358.
23. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons Inc; 2000.
24. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women [published correction appears in N Engl J Med. 1997;336:523]. N Engl J Med. 1995;332:1245-1250.
25. Lee S, Kawachi I, Berkman LF, Grodstein F. Education, other socioeconomic indicators, and cognitive function. Am J Epidemiol. 2003;157:712-720.
26. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16:217-226, 229-232.
27. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585-590.
28. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:385-391.
29. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-1218.
30. Thun MJ. Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology. 2000;11:371-374.
31. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
32. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266.
33. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11 575 patients with coronary artery disease. J Am Coll Cardiol. 1999;33:1920-1925.
34. Harpaz D, Benderly M, Goldbourt U, Kishon Y, Behar S; Israeli BIP Study Group. Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Am J Cardiol. 1996;78:1215-1219.
35. Harpaz D, Gottlieb S, Graff E, et al; Israeli Bezafibrate Infarction Prevention Study Group. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Am J Med. 1998;105:494-499.
36. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA. 2001;286:1187-1194.
37. Aspirin Myocardial Infarction Study Research Group. The Aspirin Myocardial Infarction Study: final results. Circulation. 1980;62 (pt 2):V79-V84.
38. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
39. Cook NR, Hebert PR, Manson JE, Buring JE, Hennekens CH. Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the Physicians' Health Study. Arch Intern Med. 2000;160:921-928.
40. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24:3177-3184.
41. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-313.
42. Hansson L, Zanchetti A, Carruthers SG, et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
43. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid: the HOT study; Hypertension Optimal Treatment. J Hypertens. 2000;18:629-642.
44. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice [published correction appears in Lancet. 2001;357:1134]. Lancet. 2001;357:89-95.
45. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23:254-266.
46. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840-2855.
47. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596.
48. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322-1327.
49. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal antiinflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63:6096-6101.